Chemotherapy Adjuvant *Combined Modality Therapy Cystectomy Female Humans Middle Aged Muscles Neoadjuvant Therapy *Neoplasm Invasiveness Organ Sparing Treatments Patient Selection Quality of Life Salvage Therapy Survival Rate *Urinary Bladder Neoplasms/therapy

*Cystectomy/methods Humans *Nutritional Status Postoperative Complications/*epidemiology/mortality Preoperative Period Urinary Bladder Neoplasms/*surgery Bladder cancer Complications Cystectomy Mortality Nutritional status Sarcopenia

Carcinoma Transitional Cell/*diagnostic imaging/*pathology Humans *Multiparametric Magnetic Resonance Imaging Neoplasm Staging/methods Reproducibility of Results Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnostic imaging/*pathology

5-alpha Reductase Inhibitors/therapeutic use Androgen Antagonists/therapeutic use Androgens/therapeutic use *Carcinoma in Situ Humans Male *Prostatic Neoplasms/pathology *Urinary Bladder Neoplasms/pathology *Androgen suppression therapy *Androgens *Bladder cancer *Incidence *Recurrence *Systematic review

bladder cancer mediation socioeconomic status survival systematic review Janssen and undertakes research funded by UroGen Pharma and QED Therapeutics. We can confirm all other authors have no conflicts of interest to declare.

Bayes Theorem Cystectomy Humans Laparoscopy Robotic Surgical Procedures Urinary Bladder Neoplasms/*surgery

Cystectomy Humans Neoplasm Recurrence Local/surgery Prospective Studies *Urinary Bladder Neoplasms/surgery Urologic Surgical Procedures bladder cancer repeat restaging second look transurethral resection

Adult Aged Aged 80 and over B7-H1 Antigen/genetics/*immunology Female Humans Immune Checkpoint Inhibitors/*administration & dosage *Immunotherapy Male Middle Aged Programmed Cell Death 1 Receptor/genetics/*immunology Progression-Free Survival Randomized Controlled Trials as Topic Treatment Outcome Urinary Bladder Neoplasms/genetics/immunology/mortality/*therapy efficacy immunotherapy meta-analysis safety urothelial cancer this study.

Disease Progression Humans Muscle Smooth/pathology Neoplasm Grading Neoplasm Invasiveness Neoplasm Staging Treatment Failure Urinary Bladder/pathology Urinary Bladder Neoplasms/*pathology/*therapy *Watchful Waiting Active surveillance Non-Muscle Invasive bladder cancer Urothelial neoplasm

Radical cystectomy Vi-rads muscle-invasive bladder cancer urothelial carcinoma

Vi-rads bladder cancer bladder cancer staging inter-reader agreement multiparametric magnetic resonance imaging muscle-invasive bladder cancer

加速康复外科 快速康复外科 膀胱癌 腹腔镜 meta分析

Antihypertensive Agents/*adverse effects/therapeutic use Disease Susceptibility Dose-Response Relationship Drug Humans Hypertension/complications/drug therapy/etiology Kidney Neoplasms/*epidemiology/*etiology Odds Ratio Publication Bias Risk Assessment Risk Factors Urinary Bladder Neoplasms/*epidemiology/*etiology antihypertensive medications bladder cancer kidney cancer meta-analysis risk interest.

5-ala 5-aminolaevulinic acid Hal Pdd accuracy meta-analysis bladder cancer blue light cystoscopy cystoscopy hexaminolevulinate narrow band imaging photodynamic diagnosis fluorescence consultant for Janssen Ferring Photocure Taris Spectrum Pacific Edge QED Abbvie Johnson & Johnson Seattle Genetics Nucleix Aduro and BMS. Ashish Kamat is is a consultant for Photocure. Mihir Desai is a consultant for Procept Biorobotics and Auris Surgical. Yair Lotan is a consultant for Photocure. Angela Smith is an investigator for Urogen and a consultant for FerGene Urogen and Merck.

Cystectomy/*methods Humans Neoplasm Invasiveness Urethra Urinary Bladder Neoplasms/pathology/*surgery Bladder tumor En bloc resection Meta-analysis Transurethral resection

Chemotherapy Adjuvant *Cystectomy/methods Humans Neoadjuvant Therapy Smoking/*adverse effects Survival Rate Treatment Outcome Urinary Bladder Neoplasms/drug therapy/*mortality/*surgery cigarette smoking cystectomy recurrence survival urinary bladder neoplasms

Blood Loss Surgical/statistics & numerical data Cystectomy/*methods Humans Length of Stay/statistics & numerical data Lymph Node Excision *Minimally Invasive Surgical Procedures Operative Time Postoperative Complications/epidemiology Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*surgery Bladder cancer Meta-analysis Minimally invasive Open radical cystectomy Randomized controlled trials

Case-Control Studies Humans *Polymorphism Single Nucleotide Promoter Regions Genetic Urinary Bladder Neoplasms/*genetics Vascular Endothelial Growth Factor A/*genetics Bladder cancer Meta-analysis Polymorphism Vascular endothelial growth factor competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

5 alpha reductase inhibitors androgen deprivation therapy androgen receptor bladder cancer

Carcinoma Transitional Cell/pathology/*radiotherapy/*surgery *Cystectomy Humans Neoplasm Invasiveness *Radiotherapy Adjuvant Urinary Bladder Neoplasms/pathology/*radiotherapy/*surgery Cystectomie Cystectomy Local recurrence Muscle-invasive bladder cancer Prognosis Pronostic Radiotherapy Radiothérapie Récidive locale Tumeur de vessie infiltrant le muscle